• Skip to main content
  • Skip to secondary menu
  • Skip to primary sidebar
  • Skip to footer
  • Home
  • About Us
  • Contact Us
  • Our Google News Channel
IRA vs 401k

IRA vs 401k

Retirement Options

  • Home
  • Roth IRA
  • Roth 401k
  • SEP IRA
  • Simple IRA
  • 401K
  • Finanace
You are here: Home / Finanace / Bluebird Bio shares slide 34% after company suspends trials of sickle cell disease treatment

Bluebird Bio shares slide 34% after company suspends trials of sickle cell disease treatment

February 16, 2021 by Retirement

Shares of Bluebird Bio Inc.
BLUE,
-0.02%

slid 34% in premarket trade Tuesday, after the biotech said it is temporarily suspending Phase 1/2 and Phase 3 trials of its LentiGlobin gene therapy for sickle cell disease after a report of a suspected unexpected serious adverse reaction of acute myeloid leukemia. The patient involved was treated more than five years ago and has not been diagnosed with AML, the company said in a statement. “The company is investigating the cause of this patient’s AML in order to determine if there is any relationship to the use of BB305 lentiviral vector in the manufacture of LentiGlobin gene therapy for SCD,” said Bluebird. “In addition, a second SUSAR of myelodysplastic syndrome (MDS) in a patient from Group C of HGB-206 was reported last week to the company and is currently being investigated.” The company said it will work with regulators to complete its investigation. Shares have fallen 49% in the last 12 months, while the SPDR S&P Biotech ETF
XBI,
-0.91%

has gained 69% and the S&P 500
SPX,
+0.47%

has sgained 16%.

Filed Under: Finanace

Primary Sidebar

E-mail Newsletter

More to See

Maximizing Your Retirement Savings: Expert Insights on IRAs and 401(k)s

November 23, 2024 By Roth

IRA vs 401(k): Key Differences to Help You Choose the Best Retirement Plan for 2024

November 21, 2024 By Roth

Real Estate Syndication in Indianapolis: Unlocking Investment Potential

November 15, 2024 By Retirement

Maximizing Your 401k at 55 | Retirement Strategies for Growth

October 15, 2024 By Roth

401(k) savings

Retirement Savings Options: Navigating the Path to a Secure Future

August 15, 2024 By SEO Robot

Retirement Planning

August 13, 2024 By Roth

Infographic comparing IRA vs 401(k) retirement options.

IRA and 401(k): Compare Your Retirement Options

May 20, 2024 By SEO Robot

Tags

401(k) 401(k) advantages 401(k) insights 401k at 55 401k growth strategies best retirement plan catch-up contributions exclusive listings Financial Planning financial planning 2024 Financial Security future planning Indianapolis property market Investing Investment Investment Options Investment Strategies IRA IRA benefits IRA strategies IRA vs 401k Labrosse Real Estate luxury homes luxury real estate maximize retirement savings multi-family investment Indianapolis passive income through real estate Personal Finance premium properties property syndication real estate investment real estate syndication Indianapolis Retirement retirement advice retirement investment Retirement Planning retirement planning 2024 Retirement Savings retirement savings tips retirement strategies retirement tips Savings secure retirement secure retirement funds Wealth Management

Footer

  • Privacy Policy
  • DMCA
  • Cookie Privacy Policy
  • Terms of Use
  • Google News

Recent

  • Roth IRA Contribution and Income Limits for 2025
  • Maximizing Your Retirement Savings: Expert Insights on IRAs and 401(k)s
  • IRA vs 401(k): Key Differences to Help You Choose the Best Retirement Plan for 2024
  • Real Estate Syndication in Indianapolis: Unlocking Investment Potential
  • Maximizing Your 401k at 55 | Retirement Strategies for Growth